Anita Dushyanth

John Vandermosten

Julian Harrison

- Phio Pharmaceuticals Corp. reported positive pathology results for its lead drug candidate, **PH-762**, in the final maximum dose cohort of its Phase 1b skin cancer trial on **November 3, 2025**.  **[1533040_0001437749-25-032662_ex_875368.htm:0]** **[1533040_0001437749-25-032662_phio20251023_8k.htm:1]** 
- In the final cohort, one patient achieved **100% tumor clearance** (Complete Response), another >90% clearance (Near Complete Response), and a third >50% clearance (Partial Response) for cutaneous squamous cell carcinoma (cSCC).  **[1533040_0001437749-25-032662_ex_875368.htm:0]** **[1533040_0001437749-25-032662_phio20251023_8k.htm:1]** 
- The Safety Monitoring Committee issued a **favorable review of safety data**, confirming no dose-limiting toxicities or clinically relevant treatment-emergent adverse effects at the maximum dose or in any patients treated in the trial.  **[1533040_0001437749-25-032662_ex_875368.htm:0]** **[1533040_0001437749-25-032662_phio20251023_8k.htm:1]** 
- Cumulatively, **six patients** with cSCC have achieved a complete response (100% clearance) in the Phase 1b trial.  **[1533040_0001437749-25-032662_ex_875368.htm:0]**

Phio Pharmaceuticals (PHIO)